Host |
Rabbit |
Klon |
ZR167 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon, colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa150-350) of human SATB2 protein |
Lokalisation |
Nucleus |
SATB2
|
Zeta Corporation |
ZR167 |
1 ml |
Concentrate |
CE/IVD |
Z2479RL |
-
|
Host |
Rabbit |
Klon |
ZR167 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon, colon carcinoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa150-350) of human SATB2 protein |
Lokalisation |
Nucleus |
SATB2
|
Zeta Corporation |
ZR167 |
7 ml |
Ready-to-use |
CE/IVD |
Z2479RP |
-
|
Host |
Rabbit |
Klon |
ZR167 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon, colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa150-350) of human SATB2 protein |
Lokalisation |
Nucleus |
SATB2
|
Zeta Corporation |
ZR167 |
0.5 ml |
Concentrate |
CE/IVD |
Z2479RS |
-
|
Host |
Rabbit |
Klon |
ZR167 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon, colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment (around aa150-350) of human SATB2 protein |
Lokalisation |
Nucleus |
SATB2
|
Zeta Corporation |
ZR167 |
0.1 ml |
Concentrate |
CE/IVD |
Z2479RT |
-
|
Host |
Rabbit |
Klon |
ZR339 |
Format |
Concentrate |
Methode |
IHC, FFPE |
Vorbehandlung |
Citrate o EDTA |
Positivkontrolle |
RCC, paraganglioma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding to residues in human SDHB was used as an immunogen |
Lokalisation |
Cytoplasm, mitochondria |
SDHB
|
Zeta Corporation |
ZR339 |
1.0 ml |
Concentrate |
CE/IVD |
Z2645RL |
-
|
Host |
Rabbit |
Klon |
ZR339 |
Format |
ready-to-use |
Methode |
IHC, FFPE |
Vorbehandlung |
Citrate o EDTA |
Positivkontrolle |
RCC, Paraganglioma |
Verdünnung |
--- |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding to residues in human SDHB was used as an immunogen |
Lokalisation |
Cytoplasm, mitochondria |
SDHB
|
Zeta Corporation |
ZR339 |
7 ml |
ready-to-use |
CE/IVD |
Z2645RP |
-
|
Host |
Rabbit |
Klon |
ZR339 |
Format |
Concentrate |
Methode |
IHC, FFPE |
Vorbehandlung |
Citrate o EDTA |
Positivkontrolle |
RCC, paraganglioma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding to residues in human SDHB was used as an immunogen |
Lokalisation |
Cytoplasm, mitochondria |
SDHB
|
Zeta Corporation |
ZR339 |
0.5 ml |
Concentrate |
CE/IVD |
Z2645RS |
-
|
Host |
Rabbit |
Klon |
ZR339 |
Format |
Concentrate |
Methode |
IHC, FFPE |
Vorbehandlung |
Citrate o EDTA |
Positivkontrolle |
RCC, paraganglioma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide corresponding to residues in human SDHB was used as an immunogen |
Lokalisation |
Cytoplasm, mitochondria |
SDHB
|
Zeta Corporation |
ZR339 |
0.1 ml |
Concentrate |
CE/IVD |
Z2645RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast (Carcinoma) |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to internal region of human smad3. |
Lokalisation |
Nuclear (mainly) |
SMAD3
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
519-11254 |
-
|
Host |
Rabbit |
Klon |
SP306 |
Format |
Concentrate |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide from the C-terminus of human SMAD4 protein |
Lokalisation |
Cell membrane, nucleus |
SMAD4
|
Zytomed Systems GmbH |
SP306 |
0.1 ml |
Concentrate |
RUO |
519-6060 |
-
|
Host |
Rabbit |
Klon |
SP306 |
Format |
Concentrate |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide from the C-terminus of human SMAD4 protein |
Lokalisation |
Cell membrane, nucleus |
SMAD4
|
Zytomed Systems GmbH |
SP306 |
0.5 ml |
Concentrate |
RUO |
519-6062 |
-
|
Host |
Rabbit |
Klon |
SP306 |
Format |
Concentrate |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
Synthetic peptide from the C-terminus of human SMAD4 protein |
Lokalisation |
Cell membrane, nucleus |
SMAD4
|
Zytomed Systems GmbH |
SP306 |
1 ml |
Concentrate |
RUO |
519-6064 |
-
|
Host |
Rabbit |
Klon |
EP618Y |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Appendix, Tonsil, Pancreas, Colon adenocarcinoma, Pancreatic Adenocarcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nuclear and cytoplasmic |
SMAD4
|
Biocare Medical |
EP618Y |
0.1 ml |
Concentrate |
CE/IVD |
ACI3242A |
-
|
Host |
Rabbit |
Klon |
EP618Y |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Appendix, Tonsil, Pancreas, Colon adenocarcinoma, Pancreatic Adenocarcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Nuclear and cytoplasmic |
SMAD4
|
Biocare Medical |
EP618Y |
0.5 ml |
Concentrate |
CE/IVD |
ACI3242B |
-
|
Host |
Rabbit |
Klon |
EP618Y |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Appendix, Tonsil, Pancreas, Colon adenocarcinoma, Pancreatic Adenocarcinoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Nuclear and cytoplasmic |
SMAD4
|
Biocare Medical |
EP618Y |
6 ml |
Ready-to-use |
CE/IVD |
API3242AA |
-
|
Host |
Mouse |
Klon |
1A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Smooth muscle or leiomyosarcoma. |
Verdünnung |
1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
N-Terminal decapeptide of alpha smooth muscle isoform of actin; acetylated at the N-terminus |
Lokalisation |
Cytoplasm |
Smooth Muscle Actin (SMA)
|
Zeta Corporation |
1A4 |
1.0 ml |
Concentrate |
CE/IVD |
Z2066ML |
-
|
Host |
Mouse |
Klon |
1A4 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Smooth muscle or leiomyosarcoma. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
N-Terminal decapeptide of alpha smooth muscle isoform of actin; acetylated at the N-terminus |
Lokalisation |
Cytoplasm |
Smooth Muscle Actin (SMA)
|
Zeta Corporation |
1A4 |
7 ml |
Ready-to-use |
CE/IVD |
Z2066MP |
-
|
Host |
Mouse |
Klon |
1A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Smooth muscle or leiomyosarcoma. |
Verdünnung |
1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
N-Terminal decapeptide of alpha smooth muscle isoform of actin; acetylated at the N-terminus |
Lokalisation |
Cytoplasm |
Smooth Muscle Actin (SMA)
|
Zeta Corporation |
1A4 |
0.5 ml |
Concentrate |
CE/IVD |
Z2066MS |
-
|
Host |
Mouse |
Klon |
1A4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Smooth muscle or leiomyosarcoma. |
Verdünnung |
1:100 |
Isotyp |
IgG2a /κ |
Verdünnung |
N-Terminal decapeptide of alpha smooth muscle isoform of actin; acetylated at the N-terminus |
Lokalisation |
Cytoplasm |
Smooth Muscle Actin (SMA)
|
Zeta Corporation |
1A4 |
0.1 ml |
Concentrate |
CE/IVD |
Z2066MT |
-
|
Host |
Rabbit |
Klon |
ZR169 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Leiomyoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human LMO2 protein fragment (around aa 23-140) |
Lokalisation |
Cytoplasm and Nucleus |
Smoothelin
|
Zeta Corporation |
ZR169 |
1 ml |
Concentrate |
CE/IVD |
Z2465RL |
-
|
Host |
Rabbit |
Klon |
ZR169 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Leiomyoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant human LMO2 protein fragment (around aa 23-140) |
Lokalisation |
Cytoplasm and Nucleus |
Smoothelin
|
Zeta Corporation |
ZR169 |
7 ml |
Concentrate |
CE/IVD |
Z2465RP |
-
|
Host |
Rabbit |
Klon |
ZR169 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Leiomyoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human LMO2 protein fragment (around aa 23-140) |
Lokalisation |
Cytoplasm and Nucleus |
Smoothelin
|
Zeta Corporation |
ZR169 |
0.5 ml |
Concentrate |
CE/IVD |
Z2465RS |
-
|
Host |
Rabbit |
Klon |
ZR169 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Leiomyoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human LMO2 protein fragment (around aa 23-140) |
Lokalisation |
Cytoplasm and Nucleus |
Smoothelin
|
Zeta Corporation |
ZR169 |
0.1 ml |
Concentrate |
CE/IVD |
Z2465RT |
-
|
Host |
Rat |
Klon |
YC7 |
Format |
TCS |
Methode |
F |
Verdünnung |
1:20 - 1:200 |
Isotyp |
Rat IgG2b |
Verdünnung |
Synthetic peptide corresponding to part of the native molecule |
Somatostatin
|
Zytomed Systems GmbH |
YC7 |
200 µl |
TCS |
RUO |
619-0155 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Rabbit Ig |
Lokalisation |
Cell Membrane |
Somatostatin Receptor 2A (SSTR2A)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK046-05 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Rabbit Ig |
Lokalisation |
Cell Membrane |
Somatostatin Receptor 5 (SSTR5)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK051-05 |
-
|
Host |
Rabbit |
Klon |
ZR275 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human SOX-10 protein fragment (around aa 115-269) |
Lokalisation |
Nucleus |
SOX-10
|
Zeta Corporation |
ZR275 |
1 ml |
Concentrate |
CE/IVD |
Z2591RL |
-
|
Host |
Rabbit |
Klon |
ZR275 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant human SOX-10 protein fragment (around aa 115-269) |
Lokalisation |
Nucleus |
SOX-10
|
Zeta Corporation |
ZR275 |
7 ml |
Ready-to-use |
CE/IVD |
Z2591RP |
-
|
Host |
Rabbit |
Klon |
ZR275 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human SOX-10 protein fragment (around aa 115-269) |
Lokalisation |
Nucleus |
SOX-10
|
Zeta Corporation |
ZR275 |
0.5 ml |
Concentrate |
CE/IVD |
Z2591RS |
-
|
Host |
Rabbit |
Klon |
ZR275 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant human SOX-10 protein fragment (around aa 115-269) |
Lokalisation |
Nucleus |
SOX-10
|
Zeta Corporation |
ZR275 |
0.1 ml |
Concentrate |
CE/IVD |
Z2591RT |
-
|
Host |
Rabbit |
Klon |
BC36 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung squamous cell carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1/Kappa |
Lokalisation |
Nucleus |
SOX2
|
Biocare Medical |
BC36 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3109A |
-
|
Host |
Rabbit |
Klon |
BC36 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung squamous cell carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1/Kappa |
Lokalisation |
Nucleus |
SOX2
|
Biocare Medical |
BC36 |
1 ml |
Concentrate |
CE/IVD |
ACI3109C |
-
|
Host |
Rabbit |
Klon |
BC36 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung squamous cell carcinoma |
Verdünnung |
- |
Isotyp |
IgG1/Kappa |
Lokalisation |
Nucleus |
SOX2
|
Biocare Medical |
BC36 |
6 ml |
Ready-to-use |
CE/IVD |
API3109AA |
-
|
Host |
Monospecific Mouse |
Klon |
ZM57 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal brain tissue and astrocytoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX2 protein fragment (around aa176-305) |
Lokalisation |
Nucleus |
SOX2
|
Zeta Corporation |
ZM57 |
1 ml |
Concentrate |
CE/IVD |
Z2367ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM57 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal brain tissue and astrocytoma. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX2 protein fragment (around aa176-305) |
Lokalisation |
Nucleus |
SOX2
|
Zeta Corporation |
ZM57 |
7 ml |
Ready-to-use |
CE/IVD |
Z2367MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM57 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal brain tissue and astrocytoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX2 protein fragment (around aa176-305) |
Lokalisation |
Nucleus |
SOX2
|
Zeta Corporation |
ZM57 |
0.5 ml |
Concentrate |
CE/IVD |
Z2367MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM57 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Normal brain tissue and astrocytoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX2 protein fragment (around aa176-305) |
Lokalisation |
Nucleus |
SOX2
|
Zeta Corporation |
ZM57 |
0.1 ml |
Concentrate |
CE/IVD |
Z2367MT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM171 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Human pancreas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human SOX9 protein fragment (around aa393-508) |
Lokalisation |
Nucleus |
SOX9
|
Zeta Corporation |
ZM171 |
1 ml |
Concentrate |
CE/IVD |
Z2483ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM171 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Human pancreas. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human SOX9 protein fragment (around aa393-508) |
Lokalisation |
Nucleus |
SOX9
|
Zeta Corporation |
ZM171 |
7 ml |
Ready-to-use |
CE/IVD |
Z2483MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM171 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Human pancreas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human SOX9 protein fragment (around aa393-508) |
Lokalisation |
Nucleus |
SOX9
|
Zeta Corporation |
ZM171 |
0.5 ml |
Concentrate |
CE/IVD |
Z2483MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM171 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Human pancreas. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human SOX9 protein fragment (around aa393-508) |
Lokalisation |
Nucleus |
SOX9
|
Zeta Corporation |
ZM171 |
0.1 ml |
Concentrate |
CE/IVD |
Z2483MT |
-
|
Host |
Mouse |
Klon |
BC34 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
SOX10
|
Biocare Medical |
BC34 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3099A |
-
|
Host |
Mouse |
Klon |
BC34 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
SOX10
|
Biocare Medical |
BC34 |
1 ml |
Concentrate |
CE/IVD |
ACI3099C |
-
|
Host |
Mouse |
Klon |
BC34 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
SOX10
|
Biocare Medical |
BC34 |
6 ml |
Ready-to-use |
CE/IVD |
API3099AA |
-
|
Host |
Mouse |
Klon |
BC34 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
SOX10
|
Biocare Medical |
BC34 |
25 ml |
Ready-to-use |
CE/IVD |
API3099H |
-
|
Host |
Mouse |
Klon |
BC34 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nuclear |
SOX10
|
Biocare Medical |
BC34 |
25 ml |
Ready-to-use |
CE/IVD |
AVI3099H |
-
|
Host |
Monospecific Mouse |
Klon |
ZM10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX10 protein fragment (around aa115-269) |
Lokalisation |
Nucleus |
SOX10
|
Zeta Corporation |
ZM10 |
1 ml |
Concentrate |
CE/IVD |
Z2293ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM10 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Melanoma. |
Verdünnung |
- |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX10 protein fragment (around aa115-269) |
Lokalisation |
Nucleus |
SOX10
|
Zeta Corporation |
ZM10 |
7 ml |
Ready-to-use |
CE/IVD |
Z2293MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX10 protein fragment (around aa115-269) |
Lokalisation |
Nucleus |
SOX10
|
Zeta Corporation |
ZM10 |
0.5 ml |
Concentrate |
CE/IVD |
Z2293MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM10 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Melanoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b /κ |
Verdünnung |
Recombinant human SOX10 protein fragment (around aa115-269) |
Lokalisation |
Nucleus |
SOX10
|
Zeta Corporation |
ZM10 |
0.1 ml |
Concentrate |
CE/IVD |
Z2293MT |
-
|